$Tango Therapeutics(TNGX.US) surged +53% today, driven by two catalysts stacked together: renewed attention on early-stage data from its pancreatic cancer pipeline, followed by the company's announcement of a $500 million secondary offering.

In the small-cap biotech space, this combination of 'positive data plus large financing' is quite delicate—the data ignites sentiment, the financing secures cash, pushing the stock price up short-term. However, the gap between the dilution from the offering and the pipeline's actual delivery is the key to mid-term valuation. This move looks more like an emotion-driven spike, with the real clinical readout still far away.